Anteris Technologies Global Corp Gets French Regulatory Clearance For Duravr Paradigm Global Pivotal Trial
Summary
Anteris Technologies Global Corp received French regulatory clearance for its DurAVR Paradigm global pivotal trial. The approval lets the company move ahead with a key clinical study for its transcatheter heart valve program. This development advances the company’s regulatory and clinical roadmap in cardiovascular medtech. It does not announce a new product release, financing round, acquisition, or leadership change.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected